Canbas
Basic Information
- Stock Code
- 4575
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Shizuoka Prefecture
- Establishment Year
- January 2000
- Listing Year
- September 2009
- Official Website
- https://www.canbas.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- GNI Group, Heartseed, Nexela Pharma, PeptiDream, Oncolys, SanBio, Helios, Perseus, Rena, QualiPs, Takara Bio, Japan Tissue Engineering
Overview
Canbas is a bio drug discovery venture in the pharmaceutical industry founded in 2000, specializing in research and development of cancer treatment drugs.
Current Situation
Canbas is a drug discovery venture company focusing on research and development of cancer treatment drugs, with strengths in its proprietary molecular targeting technology. By 2023, it has actively showcased research results compared to many competitors, attracting interest from partners and investors. Financially, it prioritizes investments in R&D expenses, with limited sales but aiming for future growth. With advanced technological capabilities in the bio drug discovery field and a specialized strategy, it is establishing a unique position within the pharmaceutical industry. It is also engaged in sustainability efforts, developing technologies to reduce environmental impact. Its mid-to-long-term strategy focuses on early commercialization of highly effective new drugs and global expansion, planning to obtain approvals for multiple products by around 2029. In recent years, it has expanded strategic partnerships, making progress in both R&D efficiency and fundraising. It flexibly responds to changes in the market environment and is building a foundation for sustainable growth.
Trivia
Interesting Facts
- One of the few drug discovery ventures in Japan specialized in cancer treatment drugs
- Improves drug discovery efficiency above industry average with proprietary AI platform
- Contributes to local industry revitalization as a Shizuoka Prefecture-originated bio venture
- Realizes multifaceted drug discovery support through collaboration with related companies
- Holds multiple domestic and international patents for molecular targeting technology
- Contract research services highly evaluated by universities and pharmaceutical companies domestically and internationally
- Focuses on nurturing young researchers in the bio drug discovery field
- Implements initiatives to enhance transparency in R&D
- Leads new trends in drug discovery through AI adoption
- Strengthened research investments through active fundraising since 2020
Hidden Connections
- Has formed technology partnerships and advances joint research with related companies such as Perseus and Rena
- Involved in formulating industry-standard research protocols jointly with multiple competitors
- Participates in government drug discovery support programs and receives grants
- Has multiple collaboration records with university research institutions in the Asian region
- Healthcare-related venture capital firms are listed among major shareholders
- Active research presentations at domestic and international conferences, earning high industry recognition
- Also advancing research on combination therapy technologies through joint development with medical device manufacturers
- Plays a central role in regional bio-industry revitalization projects
Future Outlook
Growth Drivers
- Expansion of demand for new molecular targeted cancer drugs
- Efficiency and cost reduction in drug discovery development via AI utilization
- Strengthening partnerships with domestic and international pharmaceutical companies
- Medium- to long-term growth expectations in the bio-pharmaceutical market
- Improved competitiveness through advanced research infrastructure development
- Differentiation through environmentally considerate product development
- Expansion of medical needs in the Asian market
- Acceleration of new drug approval processes due to regulatory easing
- Technology succession and strengthening through researcher development
- Strengthened fundraising base through public-private partnerships
Strategic Goals
- Obtain approvals for 3 or more new anti-cancer drugs
- Achieve continuous growth with annual sales exceeding 10 billion yen
- Reach 50% or more sales ratio in global markets
- Complete AI-based drug discovery platform
- Expand product lines contributing to environmental load reduction
- Promote diverse joint research projects
- Maintain and expand strong patent portfolio
- Establish proactive nurturing system for next-generation researchers
- Strengthen CSR activities for coexistence with regional communities
- Obtain domestic and international certifications for sustainability management
Business Segments
Drug Discovery Support for Pharmaceutical Companies
- Overview
- Provides advanced drug discovery support services to support new drug development by pharmaceutical companies.
- Competitiveness
- Proprietary molecular targeting technology and AI analysis capabilities
- Customers
-
- Major pharmaceutical manufacturers
- Bio ventures
- University labs
- Public research institutions
- Overseas pharmaceutical companies
- Products
-
- Drug candidate compound provision
- Molecular targeting analysis service
- Drug discovery AI tools
- Reagent development contract
- Biomarker analysis
Contract Research Services
- Overview
- Wide range of molecular evaluation and analysis services to achieve efficient contract research and development.
- Competitiveness
- Possession of cutting-edge experimental platforms
- Customers
-
- Pharmaceutical companies
- Bio companies
- University research institutions
- Medical institutions
- Government-related organizations
- Products
-
- Molecular binding evaluation
- Pharmacological assay evaluation
- In vivo testing services
- Pharmacological toxicity evaluation
- Cell culture technology provision
Technology License Provision
- Overview
- Revenue generation through licensing of innovative bio technologies.
- Competitiveness
- Strong patent portfolio
- Customers
-
- Pharmaceutical manufacturers
- R&D institutions
- Biotech companies
- Products
-
- Molecular targeting technology patents
- Drug discovery AI technology
- Reagent manufacturing technology
Therapeutic Drug Manufacturing Contract
- Overview
- Provides contract manufacturing services for therapeutic drugs using advanced manufacturing facilities.
- Competitiveness
- Strict quality control and regulatory compliance capabilities
- Customers
-
- Pharmaceutical companies
- Bio-agent manufacturers
- Products
-
- Antibody drug manufacturing
- Gene therapy drug manufacturing
- Cell therapy manufacturing
Joint Research on Drug Discovery Technology
- Overview
- Advances innovative drug discovery research in collaboration with partners.
- Competitiveness
- Flexible joint development framework
- Customers
-
- University research institutes
- Research institutions
- Corporate R&D departments
- Products
-
- New target exploration
- Drug discovery candidate substance development
- Preclinical evaluation technology
AI Technology Development Services
- Overview
- Provides technology for drug design and disease analysis utilizing AI.
- Competitiveness
- Cutting-edge AI analysis algorithms
- Customers
-
- Pharmaceutical companies
- Bioinformatics companies
- Products
-
- Drug discovery AI analysis tools
- Big data analysis
- Drug design support systems
Pharmaceutical Clinical Development Support
- Overview
- Advanced support services to streamline pharmaceutical clinical development.
- Competitiveness
- Utilization of extensive clinical data
- Customers
-
- Pharmaceutical companies
- Medical institutions
- Products
-
- Clinical trial design
- Biomarker analysis
- Data management
Quality Management Support Services
- Overview
- Provides specialized support for maintaining pharmaceutical quality.
- Competitiveness
- Advanced regulatory compliance expertise
- Customers
-
- Pharmaceutical factories
- Research facilities
- Products
-
- Manufacturing process audits
- Quality inspection technology
- Regulatory compliance support
Education and Training Services
- Overview
- Conducts specialized technical training and knowledge sharing for the industry.
- Competitiveness
- Practical and up-to-date curriculum
- Customers
-
- Pharmaceutical companies
- Universities
- Research institutions
- Products
-
- Drug discovery technology training
- AI technology training
- Regulatory compliance seminars
Competitive Advantage
Strengths
- Advanced R&D capabilities specialized in cancer treatment drugs
- Proprietary molecular targeting technology and drug discovery platform
- Strong research partnerships and investor support
- Patent portfolio in specialized areas
- Flexible joint research framework
- Specialized contract research services
- Drug discovery efficiency improvement via AI technology
- Strict quality management capabilities
- Diverse biotechnology product lineup
- Environmentally considerate technology development
Competitive Advantages
- Clear business strategy focused on cancer drug discovery and advanced technology
- Drug discovery support through fusion of AI and gene technology
- Broad B2B service deployment to diverse customer segments
- Provision capabilities for high-quality reagents and contract research
- Revenue securing through strong patents and technology licensing
- Well-equipped R&D infrastructure and talent
- Responsiveness to rapid technological innovation
- Active contributions to regional environmental conservation
- Diverse channels including specialty stores and online sales
- Strategic partnership expansion
Threats
- Long-term uncertainty and failure risks in new drug development
- Market share erosion due to competitors' technological innovations
- Increased development costs from stricter pharmaceutical regulations
- Intensified fundraising competition in the bio-pharmaceutical market
- Intellectual property risks in technology licensing
- Reduced investments due to global economic uncertainty
- Regulatory and cultural barriers in overseas expansion
- Challenges in talent acquisition
- Time delays in commercializing research results
- Impacts from global market fluctuations
Innovations
2024: Advanced AI Drug Discovery Platform
- Overview
- Significantly improved the accuracy of drug candidate exploration using proprietary AI technology.
- Impact
- 30% improvement in new drug candidate discovery speed
2023: New Development of Cancer-Specific Antibodies
- Overview
- Successfully created new antibodies specialized for cancer cells, anticipating improved therapeutic effects.
- Impact
- Progress to Phase 2 clinical trials and partnership expansion
2022: Research Efficiency Improvement via Gene Editing Technology Introduction
- Overview
- Advanced efficiency and precision in research processes using CRISPR technology.
- Impact
- 20% reduction in R&D period
2021: Environmentally Low-Impact Reagent Development
- Overview
- Commercialized environmentally considerate reagents aimed at reducing chemical substances.
- Impact
- Improved sustainability evaluation
Sustainability
- Active adoption of biomass-derived raw materials
- Introduction of renewable energy to research facilities
- Waste reduction and recycling promotion
- Promotion of low-environmental-impact product development
- Participation in regional environmental conservation activities